Why is CARE-HF such an important trial for the treatment of patients with heart failure?
Heart failure affects more than 22 million people worldwide, including 6 million in Europe and 5 million in the United States, with approximately 500,000 new patients diagnosed each year. It is the only cardiac condition that is increasing in prevalence, and it is a major cost and quality of life issue, characterized by frequent hospitalizations. The positive results from CARE-HF reinforce the need to routinely consider CRT as an adjunct to optimal medical therapy to improve patients’ quality of life, clinical status, and survival.
